Login / Signup

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD.

Nora DrickJan FugeBenjamin SeeligerMilan SpethJens Vogel-ClaussenTobias WelteHendrik Suhling
Published in: ERJ open research (2022)
Anti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies shows clinical efficacy in patients with SEA and COPD comparable to treatment response in patients with SEA alone.
Keyphrases
  • chronic obstructive pulmonary disease
  • lung function
  • air pollution
  • cystic fibrosis
  • early onset
  • stem cells
  • binding protein
  • bone marrow
  • smoking cessation